ENDRA Life Sciences Inc.

What they do

ENDRA develops Thermo-Acoustic Enhanced Ultrasound (TAEUS), a next-generation ultrasound platform for assessing liver fat, a biomarker for metabolic diseases like MASLD and MASH. The company targets pharmaceutical companies, CROs, concierge medicine, bariatric clinics, and primary care practices with a subscription-based model. It has no commercial revenue and is pre-regulatory approval for its TAEUS liver application.

Revenue drivers

• TAEUS Liver platform — Planned subscription-based recurring revenue and capital equipment sales with service/upgrade offerings; no commercial revenue recorded to date.

Recent performance

For 2025, ENDRA reported a net loss of $7.0 million, improved from an $11.5 million loss in 2024, with operating expenses down to $5.8 million from $10.8 million. Cash used in operations was $5.2 million in 2025, down from $7.4 million in 2024. As of December 31, 2025, cash was approximately $0.8 million, with an additional $2.0 million in Digital Asset Treasury. As of March 31, 2026, total assets were $3.4 million, cash was $356,462, and the company had no long-term debt.

Strategy

Management is focusing development on TAEUS for liver assessment and has implemented cost reductions, including headcount cuts, to extend operating runway. It plans to use AI/ML to improve accuracy, integrate with conventional ultrasound, and reduce system size/cost. The company initiated a Digital Asset Treasury (DAT) strategy with Arca to invest in DeFi for non-dilutive returns. In March 2026, the board began evaluating strategic alternatives, including mergers, asset sales, or sale of the company.

Risks

• Going concern and funding risk — Limited cash ($356,462 as of March 31, 2026) and a history of losses raise substantial doubt about the ability to continue as a going concern without raising significant capital.
• Regulatory and development delay — Cost reduction measures and the delay of a future FDA De Novo submission could delay or derail the commercialization of TAEUS Liver.
• Strategic alternatives uncertainty — The board's evaluation of strategic alternatives may not result in any transaction or enhance shareholder value, creating operational and strategic uncertainty.
• Digital asset treasury volatility — The DAT strategy exposes the company to volatile and unpredictable digital asset markets and regulatory developments that could adversely affect financial results.

Outlook

Management has not set a timetable for the strategic alternatives process and will continue executing operating initiatives. The delay in the FDA De Novo submission will impact the timing of development activities. Data from feasibility studies show TAEUS Liver's accuracy and repeatability, positioning it for potential future use in pharmaceutical trials and routine clinical practice.